Viking Therapeutics: Analysts See Over 216% Price Potential – Stock Climbs to $29.60
By Redaktion aktie.com
This article was created with the help of artificial intelligence.
Key Takeaways
- Viking Therapeutics closed on August 26, 2026 at $29.60, a daily gain of 1.02 percent versus the previous day's close of $29.30.
- 26 analysts rate the stock with an average price target of $93.60 (range: $83–$101), including 9 Strong Buy, 14 Buy, 3 Hold, and no sell recommendations (as of August 26, 2026).
- The company had liquid funds of $502 million as of June 30, 2026, plus a shelf program worth $500 million according to reports from August 17, 2026.
- The lead drug candidate VK2809, a selective TRβ agonist, is in Phase IIb trials for treatment of NASH and NAFLD.
- The Relative Strength Index (RSI) stood at 49.59 points on August 25, 2026 in the neutral range, following fluctuations between 42.39 and 57.48 in prior weeks.
Viking Therapeutics Inc. (VKTX) closed on August 26, 2026 at $29.60, representing a daily gain of 1.02 percent. The California-based biotech company's stock is trading significantly below analyst expectations, which point to an average price target of $93.60 – representing calculated upside potential of over 216 percent from the current price.
Strong Analyst Sentiment Supports Price Outlook
The consensus view on Viking Therapeutics is predominantly optimistic. Of 26 analysts, nine recommend the stock as a Strong Buy, another 14 recommend Buy, while only three experts hold a neutral stance. No sell recommendations are outstanding (as of August 26, 2026).
The analysts' price target range spans from $83 (lower bound) to $101 (upper bound), with a median of $95. These assessments signal considerable confidence in the company's pipeline development, which specializes in therapies for metabolic and endocrine diseases.
Pipeline with Multiple Clinical Candidates
Viking Therapeutics operates as a clinical-stage biotech company focused on developing novel treatments for metabolic and hormonal diseases. The lead drug candidate VK2809 is an orally administered, tissue-selective thyroid hormone receptor beta (TRβ) agonist currently in Phase IIb trials for treatment of non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD).
Additional pipeline candidates include VK5211, a non-steroidal selective androgen receptor modulator (SARM) in Phase II trials for patients following hip fracture surgery, and VK0612, an oral drug for type 2 diabetes being prepared for Phase IIb trials. The company is also developing VK0214, another oral candidate for metabolic indications.
Solid Liquidity Position Enables Development Continuation
At the end of the second quarter 2026 (June 30, 2026), Viking Therapeutics held liquid funds of $502 million. This capital position provides the company with financial flexibility to continue its clinical programs without immediate financing pressure.
According to media reports from August 17, 2026, the company also has access to a shelf program valued at $500 million, which can be utilized for additional capital raises if needed. Such an instrument is standard for biotech companies in clinical development phases, as financing often needs to be secured over multiple years.
Technical Indicators in Neutral Range
The Relative Strength Index (RSI) of Viking's stock stood at 49.59 points on August 25, 2026, placing it in the neutral range between 30 and 70. Values below 30 are considered oversold, values above 70 are considered overbought. The current RSI reading suggests the stock is neither technically overextended nor under heavy selling pressure.
In the preceding weeks, the RSI moved between 42.39 (August 13) and 57.48 (August 19), indicating predominantly sideways trading dynamics without strong trend development.
Trading Volume and Price Movement
On August 26, 2026, VKTX shares exhibited trading volume of around 2,013 shares. The daily range extended from $29.10 (intraday low) to $29.65 (intraday high). The closing price of $29.60 thus sat near the upper end of the daily range, suggesting buying interest during the trading session.
Compared to the previous day's close of $29.30, this represents a price gain of $0.30 or 1.02 percent. The stock trades in US dollars, which represents currency risk for German and Swiss investors.
Market Position in the Biotech Sector
Viking Therapeutics positions itself in the growing segment of metabolic diseases, which is gaining significance due to the rising prevalence of fatty liver disease and diabetes. Non-alcoholic fatty liver disease (NAFLD) affects approximately 25 percent of adults worldwide and is considered one of the most common chronic liver diseases.
Competition in this field is intense, with numerous pharmaceutical companies developing therapeutic approaches for NASH and NAFLD. Viking Therapeutics differentiates itself through the selective TRβ agonism of VK2809, which is intended to target the liver specifically without triggering systemic side effects from general thyroid hormone activation.
Risks of Clinical Development
As a company in the clinical development phase, Viking Therapeutics bears the typical risks of biotech firms with no approved products. Success hinges significantly on whether pipeline candidates successfully navigate clinical trials and obtain regulatory approvals. Failure of clinical programs or unexpected safety issues could materially impact company value.
The broad dispersion of analyst opinions – with price targets ranging from $83 to $101 – reflects the uncertainty associated with such development projects. Investors should be aware that biotech investments are volatile and substantial price swings in both directions remain possible.